在炎症性肠病患者的第三次接种疫苗之前和之后对SARS-CoV-2的抗体反应
Johanna Maria Classen1, Anna Muzalyova1, Christoph Römmele1
1Internal Medicine III, University Hospital Augsburg, Augsburg, Germany.
Digestive diseases (Basel, Switzerland)
|December 1, 2024
概括
接受免疫抑制剂的炎症性肠病 (IBD) 患者在接种第三剂疫苗后产生了显著的抗SARS-CoV-2 IgG抗体. 与对照人群相比,所有IBD患者的抗体水平都增加了补充疫苗接种.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
背景情况:
- 接受免疫抑制治疗的炎症性肠病 (IBD) 患者可能面临严重的SARS-CoV-2感染风险.
- 评估IBD患者在免疫抑制下抗体的发展至关重要.
研究的目的:
- 为了比较IBD患者和健康对照者的抗SARS-CoV-2IgG抗体水平.
- 评估免疫调节剂对第三次SARS-CoV-2疫苗接种后抗体反应的影响.
主要方法:
- 71名IBD患者和71名健康对照者的回顾性观察研究.
- 用于组比较的倾向性得分匹配.
- 在第三剂SARS-CoV-2疫苗接种前和后测量抗体水平.
主要成果:
- 在第三剂疫苗接种之前,IBD患者的抗体水平与对照人群相比相当 (p=0.088).
- TNF-α抑制剂与较低的抗体标位相关 (p=0.011),而整合素抑制剂与较高的抗体标位相关 (p=0.003).
- 所有IBD患者在第三次接种疫苗后表现出抗体标位的增加.
结论:
- 免疫调节疗法没有防止IBD患者在接种疫苗后产生抗体.
- 第三剂疫苗有效地提高了所有IBD患者的抗体水平.
- 特定的免疫调节剂对IBD患者的抗体反应有差异性影响.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
317
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
317
Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Cross-reactivity
31.0K
Overview
31.0K
Vaccinations
44.1K
Overview
44.1K
Inflammatory Bowel Disease II: Crohn's Disease
185
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
185


